A Phase 2 Study of BGJ398 in Patients With Recurrent GBM
Status:
Completed
Trial end date:
2018-10-03
Target enrollment:
Participant gender:
Summary
This is an open-label non-randomized, multicenter, phase II study of BGJ398 administered to
adult patients with histologically confirmed GBM and/or other glioma subtypes with
FGFR1-TACC1, FGFR3-TACC3 fusion and/or activating mutation in FGFR1, 2 or 3.